北海康成-B(01228)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01228 北海康成-B

已收盘 07-15 16:08:33

2.110

+0.030

+1.44%

最高2.230	最低2.070	成交量124.10万
今开2.080	昨收2.080	日振幅7.69%
总市值12.60亿	流通市值12.60亿	总股本5.97亿
成交额267.05万	换手率0.21%	流通股本5.97亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01228","market":"HK","secType":"STK","nameCN":"北海康成-B","latestPrice":2.11,"timestamp":1784102913276,"preClose":2.08,"halted":0,"volume":1241000,"delay":0,"changeRate":0.014423076923076828,"floatShares":597000000,"shares":597000000,"eps":0.03,"marketStatus":"已收盘","change":0.03,"latestTime":"07-15 16:08:33","open":2.08,"high":2.23,"low":2.07,"amount":2670520,"amplitude":0.076923,"askPrice":2.18,"askSize":2000,"bidPrice":2.11,"bidSize":3000,"shortable":0,"etf":0,"ttmEps":0.027,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784165400000},"marketStatusCode":5,"adr":0,"listingDate":1639065600000,"exchange":"SEHK","adjPreClose":2.08,"openAndCloseTimeList":[[1784079000000,1784088000000],[1784091600000,1784102400000]],"volumeRatio":2.227207,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01228","defaultTab":"news","newsList":[{"id":"1197436234","title":"北海康成-B（01228）延迟寄发药明生物服务采购框架协议通函","url":"https://stock-news.laohu8.com/highlight/detail?id=1197436234","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197436234?lang=zh_cn&edition=full","pubTime":"2026-07-09 16:36","pubTimestamp":1783586207,"startTime":"0","endTime":"0","summary":"北海康成-B7月9日公告称，公司原计划在2026年6月16日公告发布后15个营业日内向股东寄发有关与药明生物技术有限公司订立之服务采购框架协议的通函。由于公司需要额外时间编制并落实通函所载资料，寄发日期将延迟至2026年7月20日或之前。 董事会函件，说明服务采购框架协议及拟进行交易的详情与年度上限；","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649625477","title":"Baheal Wellness Industry International Trading Limited增持北海康成-B(01228.HK)305.7万股 每股作价约2.6港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2649625477","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649625477?lang=zh_cn&edition=full","pubTime":"2026-07-06 18:48","pubTimestamp":1783334934,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01228","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102060145","title":"北海康成-B更新2026年6月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1102060145","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102060145?lang=zh_cn&edition=full","pubTime":"2026-07-03 16:55","pubTimestamp":1783068907,"startTime":"0","endTime":"0","summary":"北海康成制药有限公司于2026年7月3日发布了截至2026年6月30日的证券变动月报表。报告显示，公司本月无新增普通股发行或库藏股变动，已发行股份总数维持在597,443,347股，库存股份数为0股，表明股份数目无变化。公司法定/注册股本依旧为5,000,000,000股，面值每股USD 0.00001，金额合计USD 50,000。根据本次披露，公司在2026年6月期间的股本维持不变，各项权益事务均受到香港联交所《上市规则》及相关法律法规的规范与监督。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185636720","title":"北海康成-B更新5月股份变动月报表，已发行股本增至5.97亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=1185636720","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185636720?lang=zh_cn&edition=full","pubTime":"2026-07-02 16:36","pubTimestamp":1782981366,"startTime":"0","endTime":"0","summary":"北海康成製藥有限公司于2026年7月2日发布截至2026年5月31日的股份变动月报表。报告期内，公司法定/注册股本维持在5,000,000,000股，面值每股0.00001美元，法定/注册股本总额为50,000美元，无增减变化。本月无股份购回或注销活动。此外，首发前股权激励计划保留了20,695,760股的潜在发行额度。截至本月末，公司确认其已符合适用的公众持股量要求。据公告披露，本次月报由公司董事长薛群博士签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195191655","title":"北海康成-B5月股份变动月报：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1195191655","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195191655?lang=zh_cn&edition=full","pubTime":"2026-06-04 16:37","pubTimestamp":1780562251,"startTime":"0","endTime":"0","summary":"2026年6月4日，北海康成制药有限公司公布截至2026年5月31日止的证券变动月报。报告显示，公司法定注册股本总额为5,000,000,000股，每股面值USD 0.00001，法定注册股本USD 50,000，与上月保持一致。报告期内，公司已发行股份总数为595,443,347股，无任何库藏股份，未发生新增发行、回购或注销事宜，股本结构总体保持不变。“首次公开发售前股权激励计划”及“首次公开发售后受限制股份单位计划”当月均无新股发行。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194206845","title":"北海康成-B拟回购不超过已发行股本10%的股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1194206845","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194206845?lang=zh_cn&edition=full","pubTime":"2026-06-02 17:46","pubTimestamp":1780393569,"startTime":"0","endTime":"0","summary":"北海康成-B于港交所发布公告，董事会建议在股东周年大会上寻求授权，回购不超过公司已发行股份总数10%的股份。董事会认为实施股本回购符合公司及股东的整体最佳利益。公告同时披露，自2025年6月至2026年5月，北海康成-B股价于港交所的最高交易价约为3.50港元，最低交易价约为0.14港元。董事会表示，上述交易将视公司资本状况与市况而定，若行使回购授权后影响营运资金或资本结构，将审慎评估行使安排。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"北海康成-B拟回购不超过已发行股本10%的股份","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638508174","title":"18倍“奇迹”仅4个月便腰斩，北海康成-B(01228)陷入戴维斯双杀？","url":"https://stock-news.laohu8.com/highlight/detail?id=2638508174","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638508174?lang=zh_cn&edition=full","pubTime":"2026-05-27 16:37","pubTimestamp":1779871059,"startTime":"0","endTime":"0","summary":"5月26日，北海康成-B股价大跌超10%，盘中最低价触及1.66港元，刷新年内新低，也让北海康成的股价回到去年8月12日公告宣布与百洋医药签订独家合作协议之前。2025年，港股医药板块涌现出一批“三倍股”、“四倍股”，但北海康成依旧能够凭借1824.81%的年度涨幅从其中脱颖而出。然而，反转发生在北海康成披露2025年报之后。根据北海康成在今年3月30日披露的2025年报，公司当期收入为4998.3万元，同比减少41.27%;净利润1481.8万元，同比扭亏为盈。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446583.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"18倍“奇迹”仅4个月便腰斩，北海康成-B(01228)陷入戴维斯双杀？","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01228","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194435589","title":"北海康成-B4月股份变动月报：股本保持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1194435589","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194435589?lang=zh_cn&edition=full","pubTime":"2026-05-06 18:51","pubTimestamp":1778064713,"startTime":"0","endTime":"0","summary":"北海康成製藥有限公司于2026年5月6日发布截至2026年4月30日的股份变动月报。报告显示，公司本月股本维持稳定，具体情况如下：。北海康成製藥有限公司目前注册股本为5,000,000,000股普通股，每股面值为USD0.00001，注册股本总额USD50,000。截至4月30日，已发行股份总数为595,443,347股，与上月底持平；库存股份数量为0股。期间不存在新增发行、购回或注销情况。公司表示，已符合香港联交所相关规则要求，并确认公司持股量满足公众持股比例。公告由董事长薛群博士签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144970909","title":"北海康成-B2025年收入下滑逾四成但成功扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=1144970909","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144970909?lang=zh_cn&edition=full","pubTime":"2026-04-29 22:00","pubTimestamp":1777471233,"startTime":"0","endTime":"0","summary":"北海康成制药有限公司注册于开曼群岛，主要聚焦罕见病及肿瘤创新药物的临床开发与商业化，并在中国内地、香港及台湾等地专注于相关基因及生物制剂、小分子、基因疗法等多元化产品管线的布局和合作开发。经调整后，2025年度亏损为80.4百万元，较上年同期明显下降。2025年度，北海康成-B在收入同比下降的背景下，通过终止部分海外租赁、削减经营和研发开支等举措，实现了业绩大幅改善并顺利扭亏为盈。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"北海康成-B2025年收入下滑逾四成但成功扭亏为盈","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627462768","title":"北海康成-B(01228)股东将股票存入摩根士丹利香港证券 存仓市值2.55亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2627462768","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627462768?lang=zh_cn&edition=full","pubTime":"2026-04-14 08:09","pubTimestamp":1776125360,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，4月13日，北海康成-B(01228)股东将股票存入摩根士丹利香港证券，存仓市值2.55亿港元，占比15.73%。北海康成发布公告，于2026年4月10日，本公司建议根据首次公开发售后购股权计划向一名购股权承授人(公司执行董事、董事会主席及首席执行官薛群博士)授出合共637.26万份购股权及根据首次公开发售后受限制股份单位计划向一名受限制股份单位承授人授出合共637.26万份受限制股份单位，均须待独立股东批准后方可作实。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428034.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1363072403.SGD","LU2357305700.SGD","LU1732800096.USD","161027","LU0225283273.USD","LU1548497426.USD","BK4534","BK4581","LU0912757837.SGD","LU2347655156.SGD","LU2023251221.USD","LU1989772840.SGD","LU1791710400.SGD","LU2089283258.USD","LU0098860793.USD","LU0528227936.USD","LU1720051017.SGD","IE00BZ1G4Q59.USD","LU1668664300.SGD","LU0557290698.USD","LU0795875086.SGD","LU0971096721.USD","LU0158827948.USD","LU0314104364.USD","LU0158827781.USD","LU0106261372.USD","LU2271345857.HKD","BK4504","BK4516","LU0795875169.SGD","LU1989772923.USD","01228","LU1791710582.SGD","LU0882574139.USD","BK4585","LU0320765646.SGD","LU1244550494.USD","LU1732799900.SGD","LU0106831901.USD","LU2111349929.HKD","LU1074936037.SGD","LU2089284900.SGD","LU1244550577.SGD","LU1720051108.HKD","BK4588","LU2133065610.SGD","LU0234570918.USD","LU0267386448.USD","BK4127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627101938","title":"北海康成-B(01228)授出合共637.26万份购股权及637.26万份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2627101938","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627101938?lang=zh_cn&edition=full","pubTime":"2026-04-13 06:50","pubTimestamp":1776034231,"startTime":"0","endTime":"0","summary":"智通财经APP讯，北海康成-B(01228)发布公告，于2026年4月10日，本公司建议根据首次公开发售后购股权计划向一名购股权承授人(公司执行董事、董事会主席及首席执行官薛群博士)授出合共637.26万份购股权及根据首次公开发售后受限制股份单位计划向一名受限制股份单位承授人授出合共637.26万份受限制股份单位，均须待独立股东批准后方可作实。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427473.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01228","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103927872","title":"北海康成-B2026年2月股份变动月报：新增发行3万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1103927872","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103927872?lang=zh_cn&edition=full","pubTime":"2026-04-09 16:51","pubTimestamp":1775724689,"startTime":"0","endTime":"0","summary":"北海康成製藥有限公司于2026年4月9日公布2026年2月股份变动月报。报告期为2026年2月1日至2026年2月28日。于本月末，公司已发行普通股数量为511,252,234股，较上月底增加30,000股。根据月报披露，上述股份增发主要来自“首次公开发售后购股权计划”的期权行使，当月行使期权产生30,000股新增发行，获得认购资金约80,400港元。报告期内，没有购回、注销或库藏股变动情形。截至2026年2月底，公司公众持股量符合香港联交所相关规定，股本规模相对保持稳定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178704097","title":"北海康成-B3月股份变动月报：股本增至5.95亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=1178704097","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178704097?lang=zh_cn&edition=full","pubTime":"2026-04-09 16:50","pubTimestamp":1775724650,"startTime":"0","endTime":"0","summary":"北海康成製藥有限公司于2026年4月9日发布3月股份变动月报表。报告期为截至2026年3月31日。公司法定股本维持5,000,000,000股，面值每股0.00001美元，注册股本总额50,000美元，与上月底无变化。报告期内已发行股份从上月底的511,252,234股增至595,443,347股，新增发行84,191,113股。本月底公司无库藏股，无购回或注销股份记录。月报显示，截至2026年3月31日，公司已满足香港联交所的相关公众持股量要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132196492","title":"北海康成更新1月股份变动月报表，股本增至511,222,234股","url":"https://stock-news.laohu8.com/highlight/detail?id=1132196492","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132196492?lang=zh_cn&edition=full","pubTime":"2026-04-09 16:47","pubTimestamp":1775724449,"startTime":"0","endTime":"0","summary":"北海康成製藥有限公司于2026年4月9日发布截至2026年1月31日的股份变动月报表。公告显示，公司本月注册股本维持不变，法定股本依旧为50,000美元，总股数上限为5,000,000,000股。本月已发行股份由上月底的511,120,234股增至511,222,234股，新增102,000股。公司在报告期内未发生库藏股、回购及注销事宜。此外，公告说明公司另有首次公开发售前股权激励计划及首次公开发售后受限制股份单位计划，但本月未有新股发行及转让事宜。截至报告期末，北海康成的股本数量为511,222,234股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177582806","title":"北海康成-B更新2025年11月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1177582806","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177582806?lang=zh_cn&edition=full","pubTime":"2026-04-09 16:47","pubTimestamp":1775724433,"startTime":"0","endTime":"0","summary":"北海康成制药有限公司于2026年4月9日公布2025年11月股份变动月报。报告期截至2025年11月30日，公司法定股本维持在5,000,000,000股普通股，总额USD50,000，与上月一致。期末已发行股份数为510,826,484股，较上月无变化，库存股份数为0。报告期内公司未发生任何新增发行、购回或注销股份行为。若全部行使，可影响已发行股份28,245,342股。此外，“首次公开发售前股权激励计划”下可发行21,858,960股，本月无变动。公司同时确认满足香港联交所相关上市规则的公众持股量要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153467582","title":"北海康成-B更新2025年12月股份变动月报表，股本小幅增加","url":"https://stock-news.laohu8.com/highlight/detail?id=1153467582","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153467582?lang=zh_cn&edition=full","pubTime":"2026-04-09 16:47","pubTimestamp":1775724422,"startTime":"0","endTime":"0","summary":"北海康成製藥有限公司（股票代码：01228）于2026年4月9日发布2025年12月股份变动月报表。公告显示，公司法定股本保持USD 50,000不变；截至2025年12月31日，已发行普通股由上月底的510,826,484股增至511,120,234股，单月新增293,750股。\n其中，首次公开发售后购股权计划在报告期内行使93,750股，募资金额为HKD 99,037.5；同时，首次公开发售前股权激励计划当月发行200,000股。报告期内无任何购回或注销行为，库藏股数目维持为0。截至月末，公司已确认满足香港联交所上市规则的公众持股量要求。公告由董事长薛群博士签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189362957","title":"北海康成-B更新10月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1189362957","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189362957?lang=zh_cn&edition=full","pubTime":"2026-04-09 16:42","pubTimestamp":1775724170,"startTime":"0","endTime":"0","summary":"北海康成製藥有限公司于2026年4月9日发布截至2025年10月31日的股份变动月报表。报告显示，公司本月内无新增发行或回购活动，整体股本情况保持稳定。公司经公告确认，截至10月底，其法定注册股本维持在5,000,000,000股普通股，面值为每股USD 0.00001，法定注册股本总额继续为USD 50,000。公司于月报中再度确认其已达到适用的公眾持股量要求。至此，公司截至10月底的股本维持在510,826,484股，未发生任何购回或注销行为。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170862215","title":"北海康成-B更新9月股份变动月报表，已发行股份增至510,826,484股","url":"https://stock-news.laohu8.com/highlight/detail?id=1170862215","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170862215?lang=zh_cn&edition=full","pubTime":"2026-04-09 16:42","pubTimestamp":1775724122,"startTime":"0","endTime":"0","summary":"北海康成制药有限公司于2026年4月9日发布截至2025年9月30日的股份变动月报表。报告期内公司法定股本维持每股面值0.00001美元、共5,000,000,000股，注册股本总额保持在50,000美元。报告期初公司已发行股份为499,809,788股，期内新增发行股份11,016,696股，报告期末已发行股份总数增至510,826,484股。有关股份期权中，本月内186,000股期权已失效，另外在报告期内行使的购股权筹得现金约546,205港元。公司表示，目前已遵守香港联交所的最低公众持股量要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162693704","title":"异动解读 | 北海康成-B(01228)盘中大涨5.32%，因2025年度业绩扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=1162693704","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162693704?lang=zh_cn&edition=full","pubTime":"2026-03-31 16:02","pubTimestamp":1774944174,"startTime":"0","endTime":"0","summary":"北海康成-B(01228)今日盘中股价大幅上涨5.32%，引起了市场关注。消息面上，公司公布了截至2025年12月31日止的年度业绩，成功实现扭亏为盈。根据公告，公司股东应占溢利为1481.8万元人民币，而上年同期为亏损4.43亿元人民币，每股盈利0.03元人民币，公司决定不派息。尽管全年收入同比下降41.2%至5000万元人民币，但盈利能力的显著改善被视为推动股价上涨的关键因素。此次业绩逆转标志着公司经营状况的积极变化，增强了投资者对公司未来发展的信心，从而在交易时段内提振了股价。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623732219","title":"北海康成-B(01228)：练少娥获委任为法律程序文件代理人","url":"https://stock-news.laohu8.com/highlight/detail?id=2623732219","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623732219?lang=zh_cn&edition=full","pubTime":"2026-03-31 06:27","pubTimestamp":1774909670,"startTime":"0","endTime":"0","summary":"智通财经APP讯，北海康成-B 发布公告，公司之联席公司秘书之一黄伟超先生(黄先生)已提出辞任本公司联席公司秘书职务。于黄先生辞任后，马女士亦已获委任为授权代表之一，以取代其职务，自2026年3月30日起生效;及于黄先生辞任后，练少娥女士(练女士)已获委任为法律程序文件代理人，以取代其职务，自 2026年3月30日起生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422586.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01228"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ssitimber.com.hk","stockEarnings":[{"period":"1week","weight":0.0612},{"period":"1month","weight":0.0452},{"period":"3month","weight":-0.2091},{"period":"6month","weight":-0.0631},{"period":"1year","weight":1.4471},{"period":"ytd","weight":-0.1875}],"compareEarnings":[{"period":"1week","weight":0.0359},{"period":"1month","weight":-0.0153},{"period":"3month","weight":-0.0619},{"period":"6month","weight":-0.0959},{"period":"1year","weight":0.0057},{"period":"ytd","weight":-0.0503}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"CANbridge Pharmaceuticals Inc是一家全球生物制药公司。该公司专注于罕见病转化疗法的研究、开发和商业化。该公司拥有一个药物组合，其中包括三种获批药物和八种资产的管线，针对尚未满足需求的罕见病适应症。这些包括亨特综合征和其他溶酶体贮积症、阵发性睡眠性血红蛋白尿和其他补体介导的疾病、血友病A、代谢性疾病、罕见胆汁淤积性肝病和神经肌肉疾病。其管线包括Hunterase、Livmarli、CAN106和CAN103。Hunterase是一种酶替代疗法，用于治疗II型粘多糖贮积症（MPS II），也称为亨特综合征。Livmarli是一种口服、吸收率极低、可逆性的回肠胆汁酸转运蛋白抑制剂，正在开发中，用于治疗罕见的胆汁淤积性肝病，包括Alagille综合征和进行性家族性肝内胆汁淤积症。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.126185},{"month":2,"riseRate":0.4,"avgChangeRate":0.011895},{"month":3,"riseRate":0.2,"avgChangeRate":-0.095239},{"month":4,"riseRate":0.2,"avgChangeRate":-0.054254},{"month":5,"riseRate":0,"avgChangeRate":-0.09989},{"month":6,"riseRate":0.4,"avgChangeRate":0.271134},{"month":7,"riseRate":0.4,"avgChangeRate":0.391676},{"month":8,"riseRate":0.25,"avgChangeRate":0.239858},{"month":9,"riseRate":0.75,"avgChangeRate":0.161514},{"month":10,"riseRate":0,"avgChangeRate":-0.161874},{"month":11,"riseRate":0.25,"avgChangeRate":-0.205763},{"month":12,"riseRate":0.5,"avgChangeRate":0.059277}],"exchange":"SEHK","name":"北海康成-B","nameEN":"CANBRIDGE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"北海康成-B(01228)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供北海康成-B(01228)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"北海康成-B,01228,北海康成-B股票,北海康成-B股票老虎,北海康成-B股票老虎国际,北海康成-B行情,北海康成-B股票行情,北海康成-B股价,北海康成-B股市,北海康成-B股票价格,北海康成-B股票交易,北海康成-B股票购买,北海康成-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"北海康成-B(01228)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供北海康成-B(01228)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}